MC3 was founded in 1991 by Dr. Robert Bartlett, and Scott Merz, PhD as a spin-off from the University of Michigan. Over the past three decades, MC3 has passionately advanced the innovation of intellectual property related to artificial heart and lung technologies and has conducted important translational research to serve the extracorporeal life support community by solving complex clinical technology challenges.
Headquartered just outside of Ann Arbor in Dexter, Michigan, the company has entered an exciting new chapter as a healthcare device provider under the new ownership of Robert Foster, a visionary medical device manufacturing pioneer with a keen focus on cardiopulmonary devices solutions. The company is re-imagined as MC3 Cardiopulmonary, with the vision and goal to serve the global community by creating life restoring medical devices that address acute and chronic unmet cardiopulmonary clinical needs. ECMO (extracorporeal membrane oxygenation) is the most advanced form of life support, allowing gas exchange through blood carried outside of the body, instead of the airway. MC3 Cardiopulmonary is committed to developing innovative, safe, and effective ECMO products. Together with the ECMO community and our strategic global distribution partner Medtronic, we will transform healthcare by delivering ECMO broadly to patients suffering from acute respiratory and cardiac failure across a wide therapy spectrum.